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Severe acute respiratory syndrome (SARS) is a highly contagious and life threatening disease, with a fatality
rate of almost 10%. The etiologic agent is a novel coronavirus, severe acute respiratory syndrome coronavirus
(SARS-CoV), with animal reservoirs found in bats and other wild animals and thus the possibility of reemer-
gence. In this study, we first investigated at 6 years postinfection whether SARS-specific memory T cells persist
in SARS-recovered individuals, demonstrating that these subjects still possess polyfunctional SARS-specific
memory CD4! and CD8! T cells. A dominant memory CD8! T cell response against SARS-CoV nucleocaspid
protein (NP; amino acids 216 to 225) was then defined in SARS-recovered individuals carrying HLA-B*40:01,
a HLA-B molecule present in approximately one-quarter of subjects of Asian ethnicities. To reconstitute such
a CD8! T cell response, we isolated the alpha and beta T cell receptors of the HLA-B*40:01-restricted
SARS-specific CD8! T cells. Using T cell receptor gene transfer, we generated SARS-specific redirected T cells
from the lymphocytes of normal individuals. These engineered CD8! T cells displayed avidity and functionality
similar to that of natural SARS-specific memory CD8! T cells. They were able to degranulate and produce
gamma interferon, tumor necrosis factor alpha, and macrophage inflammatory proteins 1" and 1# after
antigenic stimulation. Since there is no effective treatment against SARS, these transduced T cells specific for
an immunodominant SARS epitope may provide a new avenue for treatment during a SARS outbreak.
No severe human disease associated with coronaviruses was
reported until the outbreak of severe acute respiratory syn-
drome (SARS) in late 2002 in Guangdong, China (22, 29). It
affected more than 8,000 patients and caused nearly 800 deaths
in more than 30 countries. The etiological agent of the syn-
drome was identified as a novel coronavirus termed SARS
coronavirus (SARS-CoV) (5, 10, 17). The SARS-CoV genome
encodes the replicase genes (open reading frame 1a [ORF1a]
and ORF1b) and four structural proteins (spike [S], nucleo-
capsid [NP], membrane [M], and envelope [E]), together with
eight other accessory proteins, namely, 3a, 3b, ORF6, 7a, 7b,
8a, 8b, and 9b.
Recent studies have indicated the importance of T cells in
viral clearance during a primary infection of SARS-CoV (3,
32). SARS-specific memory T cell responses against the struc-
tural proteins, S, M, E, and NP are present in SARS recovered
patients (6, 11, 13), but it is unclear whether SARS elicits a
lasting memory T cell response.
Most studies focus on the surface glycoprotein S protein,
and to date several cytotoxic-T-lymphocyte (CTL) epitopes
have been identified in the S protein (15, 25, 26, 27, 28, 33).
However, a detailed analysis and epitope definition of T cell
responses against SARS 3a (the largest accessory protein
and unique to the SARS-CoV) (14, 16) and NP proteins is
lacking. Here, we analyzed the presence and function of
SARS memory T cell response at 6 years postinfection. We
defined a dominant SARS-specific T cell response com-
monly detectable in Asian individuals and isolated its
SARS-specific T cell receptors. We then demonstrated the
possibility to generate SARS-specific T cells from lympho-
cytes of healthy uninfected individuals through T-cell-recep-
tor (TCR) gene transfer. TCR gene transfer has emerged, in
several studies, as a way to develop cell-based therapy for
chronic viral diseases such as hepatitis C and B (8, 31) and
malignancies such as melanoma (21). In addition, adoptive
transfer of virus-specific T cells can also protect subjects
that undergo immunosuppressive treatment from human cy-
tomegalovirus (HCMV) or Epstein-Barr virus (EBV) reac-
tivation (4, 7). Thus, the identification of SARS epitopes
and production of SARS-specific TCR-redirected T cells can
provide prophylactic or therapeutic opportunities against this
infection.
MATERIALS AND METHODS
Subjects. Sixteen recovered SARS individuals (6 years postinfection) were
enrolled in the present study from the Singapore General Hospital (Singapore).
All of the participants had been diagnosed as having SARS based on clinical
examination during the period from March to May 2003 according to the World
Health Organization’s definition of SARS (30). The diagnosis was further con-
firmed by serological detection of SARS-CoV-specific antibodies detected by
enzyme-linked immunosorbent assay and/or reverse transcription-PCR for SAR-
CoV mRNA. Five normal subjects without any contact history with SARS pa-
* Corresponding author. Mailing address: Singapore Institute for
Clinical Sciences, A*STAR (Agency for Science, Technology, and
Research), Brenner Center for Molecular Medicine, 30 Medical Drive,
Singapore 117609, Singapore. Phone: 65-6407 0091. Fax: 65-6776 6837.
E-mail: antonio@sics.a-star.edu.sg.
! Published ahead of print on 3 August 2011.
10464
tients were used as negative controls. This study was approved by the Centralized
Institutional Review Board of the Singapore Health Services Pte, Ltd. (Singa-
pore).
Isolation of PBMC and in vitro expansion of SARS-specific T cells. Peripheral
blood mononuclear cells (PBMC) were isolated from fresh heparinized blood by
Ficoll-Hypaque density gradient centrifugation and resuspended in AIM-V me-
dium (Invitrogen, Carlsbad, CA) with 2% pooled human AB serum. T cells were
used either directly ex vivo or after a 10-day antigen-specific in vitro stimulation
as previously described (24). Briefly, 20% of the PBMC were first stimulated with
10 !g of all the overlapping peptides/ml for 1 h at 37°C and then washed before
coculture with the remaining PBMC in AIM-V medium with 2% pooled human
AB serum supplemented with interleukin-2 (IL-2; R&D Systems, Abingdon,
United Kingdom) at 20 U/ml and seeded at 1 ml/well in 24-well plates.
Synthetic peptides. Two panels of 15mer peptides overlapping by 10 residues
covering NP (total, 83 peptides) and accessory 3a protein (total, 53 peptides)
were used. The peptides were purchased from Chiron Mimotopes (Victoria,
Australia) at a purity above 80%, and their composition was confirmed by mass
spectrometry analysis. The NP peptides were pooled in a 9-by-9 matrix contain-
ing 9 or 10 peptides/pool, whereas the 3a peptides were pooled in a 7-by-8 matrix
containing 6 to 8 peptides/pool, respectively. All peptides were diluted at 40
mg/ml in dimethyl sulfoxide and then further diluted in RPMI 1640 medium at
a working dilution (between 10 and 1 mg/ml).
IFN-$ ELISPOT assay. Using the panel of 15mer peptides pooled in 33
mixtures as described above, SARS-specific T cell responses were analyzed as
previously described (8) in gamma interferon (IFN-") enzyme-linked immuno-
spot (ELISPOT) assays either ex vivo using frozen PBMC or short-term poly-
clonal T cell lines previously expanded in vitro by 10 days of stimulation with the
same peptide mixtures. The number of IFN-"-producing cells was expressed in
spot-forming units (SFU) per 1 # 105 cells (ex vivo) or 5 # 104 cells (in vitro).
Positive controls consisted of PBMC stimulated with staphylococcal enterotoxin
B (SEB) or phytohemagglutinin (PHA). Wells were considered positive if they
had values at least two times the background value and the number of spots was
greater than 30. A positive peptide was identified as the common peptide be-
longing to both the “number” and “alphabet” pools that gave positive ELISPOT
responses.
Intracellular cytokine staining and degranulation assays. In vitro-expanded T
cells were incubated in medium alone (negative control) or with viral peptides (5
!g/ml) for 5 h in the presence of brefeldin A (10 !g/ml). The cells were stained
with anti-CD8 (phycoerythrin [PE]-Cy7) or anti-CD4 PE-Cy7 and anti-CD3
(peridinin chlorophyll protein [PerCP]-Cy5.5) (BD Pharmingen, San Jose, CA)
for 30 min at 4°C and washed once and then fixed and permeabilized using
Cytofix/Cytoperm fixation/permeabilization (BD Biosciences, San Jose, CA),
according to the manufacturer’s instructions. Intracellular staining was per-
formed with anti-IFN-"-PE (BD Biosciences) for 30 min at 4°C, followed by
washing and analysis by flow cytometry. To assess the degranulation activity,
anti-CD107a (fluorescein isothiocyanate [FITC]) antibody (BD Pharmingen, San
Diego, CA) was added to all wells at the beginning of the 5 h of incubation with
T cells. After incubation, the cells were washed and stained as described above.
Polyfunctional T cell assays were performed using the antibodies against the
following: (i) Th1/Th2-associated cytokines (IFN-", tumor necrosis factor alpha
[TNF-$], IL-2, IL-4, IL-10, and IL-21) or (ii) inflammatory cytokines (IFN-",
IL-8, macrophage inflammatory protein 1$ [Mip1$], Mip1%, granulocyte-mac-
rophage colony-stimulating factor [GM-CSF], and IL-17a).
Major histocompatibility complex restriction for CD8! T cell responses. The
HLA phenotype for each of 16 individuals who had recovered from SARS
(SARS-recovered individuals) was determined by PCR amplification and se-
quencing based typing method as described previously (23). EBV-transformed
lymphoblastoid B cell lines (EBV-LCL) of defined HLA phenotype (kindly
provided by Chan Soh Ha, National University of Singapore) were used as
antigen-presenting cells.
Isolation of a NP44-specific CD8! T cell clone and TCR " and # chain DNA.
A NP44-specific CD8& T cell clone was generated from the HLA-B*4001&
SARS patient 1. Short-term lines were made by stimulating PBMC with 5 !g of
NP44 peptide/ml for 10 days. NP44-specific CD8 T cells were labeled with
CD107a-PE for 2 h in 37°C, followed by staining with CD8-APC for 30 min at
4°C and purification by fluorescence-activated cell sorting (FACS). CD8 T cells
were then cloned by limiting dilution assay, and clonal populations were ex-
panded in AIM-V and 20 U of IL-2, 10 ng of IL-7, and 10 ng of IL-15 (R&D
Systems)/ml with 1 !g of PHA (Sigma-Aldrich, Dorset, United Kingdom)/ml,
using allogeneic irradiated PBMC as feeder cells.
Total RNA was isolated from the T cell clone using TRIzol (Invitrogen). The
SARS NP44 TCR $ and % chains were cloned as described previously (8).
Briefly, the TCR $ and % chains of the NP44 TCR were cloned by RACE (rapid
amplification of cDNA ends)-PCR using a GeneRacer kit (Invitrogen). Se-
quence analysis of the cDNA clones revealed that the T cell clone expressed a
single TCR $ chain of AV4.0/AJ28.0/AC and a % chain of BV4.3/BJ2.1/
BD1.0/BC according to IMGT/V-Quest (http://www.imgt.org) (2). After func-
tional confirmation of the TCR, a codon-optimized, 2A-linked construct was
synthesized and cloned into the MP-71 vector for expression in primary human
T cells.
Retroviral transduction. A total of 2 # 106 Phoenix amphotropic packaging
cells were seeded into 10-cm tissue culture dishes 24 h prior to transfection.
Phoenix cells were transiently cotransfected using calcium phosphate with 18 !g
of TCR construct, together with 6 !g of amphotropic envelope for 24 h. Iscove
modified Dulbecco medium (IMDM) was replaced with AIM-V supplemented
with 2% human AB serum, and phoenix cells were incubated for an additional
24 h before retroviral supernatants were collected for transduction.
PBMC from normal healthy donors were stimulated with 600 U of IL-2 (R&D
Systems)/ml and 50 ng of anti-CD3 (OKT-3; eBioscience, San Diego, CA)/ml for
48 h. Untreated 24-well tissue culture plates were coated with 30 !g of retronec-
tin (Takara Bio, Otsu Shiga, Japan)/ml overnight at 4°C 1 day prior to transduc-
tion. The wells were washed with Hanks balanced salt solution and then blocked
with phosphate-buffered saline plus 2% bovine serum albumin. The lymphocytes
were harvested, washed, and counted, and then 5 # 105 cells were plated into
retronectin-coated wells and mixed with retroviral supernatants collected as
described above. Mock-transduced cells, included as a negative control, were
cultured with the supernatant from untransfected phoenix cells. Lymphocytes
were incubated for 24 h in the retroviral supernatant, the medium was replaced,
and the cells were maintained in AIM-V 2% human AB serum plus 100 U of
IL-2/ml. After 3 days, the T cells were stained with anti-CD8 PE-Cy7 (BD
Biosciences) and anti-V%4.3 PE (Beckman Coulter, Fullerton, CA).
Production of target cells expressing SARS antigens. For T cell recognition of
endogenously expressing SARS antigen, target cells were infected with recom-
binant vaccinia virus encoding either the SARS NP or S protein at multiplicity of
infection (MOI) of 5 for 1 h at 37°C. After infection, the virus was removed, and
the cells were washed and resuspended in AIM-V 2% human AB serum at 105
cells/well. Each well was then treated with 10 U of IFN-$ and IFN-" each/ml. An
equal number of NP44-specific CD8 T cells or NP44 TCR-transduced T cells
(105) was added to the target cells for 5 h in the presence of brefeldin A (10
!g/ml) and stained as described above for degranulation activity with anti-
CD107a-FITC antibody.
RESULTS AND DISCUSSION
Memory T cell responses against SARS in recovered indi-
viduals. To investigate the presence and functional profile of
SARS-specific memory T cell responses against NP and 3a
SARS-CoV proteins, peripheral blood of 16 Asian subjects
who recovered from SARS-CoV infection was collected 6 years
postinfection. As negative controls, PBMC of five healthy in-
dividuals with no prior contact history with SARS were in-
cluded. PBMC were stimulated directly ex vivo or after in vitro
expansion with mixtures of synthetic peptides (15mer peptides
overlapping by 10 residues) spanning the entire amino acid
sequence of the NP and 3a proteins and analyzed using IFN-"
ELISPOT assay. The frequency of IFN-"-producing SFU did
not exceed 10 in the direct ex vivo ELISPOT assay (Fig. 1A),
and no significant difference was observed between healthy and
SARS-exposed individuals. In contrast, high frequencies of
IFN-"-producing SFU were detected in wells containing in
vitro-expanded PBMC from SARS-recovered individuals (Fig.
1A), while no response was found in PBMC from healthy
individuals. Figure 1B summarizes the ELISPOT data of the 16
SARS individuals after in vitro expansion of the PBMC. The
data showed that 9 of the 16 SARS individuals displayed high
frequencies of SFU against the NP protein, the 3a protein, or
both proteins. Three individuals had a single response, and
others showed multiple responses. These results showed that
SARS-specific memory T cells are present in SARS-recovered
individuals 6 years after infection, even though the frequency
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of these cells is low. Interestingly, in contrast to our study, T
cell responses can be observed directly in the ex vivo ELISPOT
assay conducted in a study by Li et al. (11) in which PBMC
were obtained from patients 1 year postinfection. Such com-
parison suggests that the frequency of SARS-specific memory
T cells progressively declines with time. This hypothesis is also
supported by another study that monitored immune response
in SARS individuals over a 2-year period and showed that CTL
responses decline over time at 3, 6, and 18 months postinfec-
tion (12).
To confirm the ELISPOT assay results and to define
whether the IFN-"-producing cells were CD4& or CD8& T
cells, in vitro-expanded T cell lines of every positive individual
were tested with anti-CD4 and anti-CD8 specific antibodies
and intracellular staining for IFN-". Figure 1C and Table 1
show the complete profile of T cell responses detected in the
FIG. 1. Memory T cell responses in SARS-recovered individuals. (A) ELISPOT analysis was performed on PBMC directly ex vivo (top panels)
and after 10 days of in vitro expansion (bottom panels) using the same pools of peptides (3a and NP). The data for one healthy and one
SARS-recovered individual are displayed. Each bar represents the response to an individual peptide mixture in SFU per 1 # 105 or 5 # 104 cells.
The threshold of positivity is defined as two times the mean SFU of the unstimulated control (N) and '30 SFU. Positive control (P) was included
with cells stimulated by SEB. (B) Summary of the positive ELISPOT results for all 16 SARS-recovered individuals after 10 days of in vitro
expansion using the same pools of peptides. (C) IFN-" production by SARS-specific CD8& and CD4& T cells determined by intracellular cytokine
staining. Distribution of CD4& (left panel) and CD8& (right panel) responses between the two proteins tested. The data are expressed as the
percentage of the total number of CD4& or CD8& T cells. (D) Functional assay measuring IFN-" production by NP44-specific CD8& T cells after
stimulation with different concentrations of the 8mer (GETALALL) and (ETALALLL), 9mer (GETALALLL), and 10 mer (GETALALLLL)
NP44 peptides. Target cells (HLA-B*40:01-positive EBV-LCLs) were pulsed with the indicated peptide concentrations. The data are expressed
as the percentage of the total number of CD8& T cells producing IFN-".
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recruited individuals. More than 50% of the convalescent
SARS individuals had positive T cell responses against at least
one of the two proteins, and 25% of them had responses
against both proteins. CD4& T cell responses were observed in
six of nine responsive individuals, while CD8& T cell responses
were detectable in five subjects. Helper CD4& T cells recog-
nized both 3a (six different epitopes recognized) and NP (four
different epitopes) proteins. Strong responses against the NP
or 3a protein were observed equally in individuals with multi-
ple CD4 responses. Although NP or 3a proteins were equally
immunogenic for helper T cell responses, CD8& T cells rec-
ognized preferentially the NP protein (six of seven CD8& T cell
responses were specific for epitopes present on NP protein)
with a single exception of peptide 3a2 (amino acids [aa] 6 to 20;
RFFTLGSITAQPVKI) (Fig. 1C). This peptide was able to
elicit both CD8& and CD4& responses, as already observed in
another study (11). Importantly, three of the five individuals
who showed a SARS-specific CD8& T cell response recognize
the aa 216 to 230 region (NP44 peptide) of the SARS-CoV NP
protein (Table 1). All of the subjects carried the HLA-B*40:01
allele. The dominant CD8& T cell response was further char-
acterized using truncated 8-, 9-, and 10mer peptides and HLA-
B*40:01-positive and -negative target cells. We verified that
the 10mer peptide (GETALALLLL; aa 216 to 225) was the
more efficient peptide for activation of NP44-specific CD8& T
cells only when presented by HLA-B*40:01-positive target cells
(Fig. 1D).
The functionality of SARS-specific CD4& and CD8& mem-
ory T cells was also analyzed. We used polychromatic flow
cytometry to detect the cytokines IFN-", TNF-$, IL-2, IL-4,
IL-10, and IL-21 (defined as the Th1/Th2 panel) and the cy-
tokines IFN-", IL-8, Mip1$, Mip1%, GM-CSF, and IL-17a
(defined as the antiviral inflammatory panel). The low fre-
quency of SARS-specific CD4& and CD8& T cells in the pe-
ripheral blood did not allow us to test their functional profile
directly ex vivo, and therefore the cytokine production profile
of CD8& T cells specific for the aa 216 to 230 NP peptide and
CD4& T cells specific for the aa 6 to 20 3a peptide were
expanded and tested after 10 days of in vitro expansion. The
majority (52%) of SARS-specific memory CD4& T cells were
polyfunctional, producing simultaneously the Th1 cytokines
IFN-", TNF-$, and IL-2 (Fig. 2A). Instead, a minority of
SARS-specific CD4& cells produce inflammatory chemokines
(Mip1$, Mip1%, and GM-CSF) (Fig. 2B), while no CD4& T
cells producing IL-10, IL-4, IL-17a, or IL-21 were detected.
SARS-specific CD8& T cells functional profile was different
TABLE 1. Summary of CD4& and CD8& memory T cell responses in SARS-recovered individuals
Patient HLA profile Peptide(s) aa positiona Peptide sequence Type ofresponse
% IFN-"&, CD4&, or
CD8& cells
1 A*02:07 A*02:01 3a11 51–65 AFLAVFQSATKIIAL CD4 0.23
B*46:01 B*40:01 NP44 216–230 GETALALLLLDRLNQ CD8 2.26
Cw*01:03 Cw*15:02
3 A*24:02 A*11:02 NP44 216–230 GETALALLLLDRLNQ CD8 1.54
B*40:01 B*48:01
Cw*08:03 Cw*07:02
7 A*26:01 A*02:01 NP66 326–340 TPSGTWLTYHGAIKL CD4 1.48
B*08:01 B*57:01 3a2 6–20 RFFTLGSITAQPVKI CD4 0.65
Cw*07:02 Cw*06:02 3a40 169–210 GVKDYVVVHGYFTEV CD4 1.54
3a42 206–220 YFTEVYYQLESTQIT CD4 0.43
8 A*24:07 A*24:07 3a2 6–20 RFFTLGSITAQPVKI CD4 0.38
B*15:02 B*58:01
Cw*03:02 Cw*08:01
9 A*11:01 A*24:07 NP66 326–340 TPSGTWLTYHGAIKL CD4 5.22
B*15:02 B*40:01 3a14 66–80 NKRWQLALYKGFQFI CD4 5.89
Cw*08:01 Cw*03:04
13 A*31:01 A*02:01 NP44 216–230 GETALALLLLDRLNQ CD8 2.76
B*13:01 B*40:01 NP65 321–335 IGMEVTPSGTWLTYH CD8 0.15
Cw*03:04 Cw*03:04
14 A*31:01 A*02:06 NP26 126–140 ANKEGIVWVATEGAL CD4 0.49
B*40:01 B*40:01 NP62 306–320 AQFAPSASAFFGMSR CD4 0.42
Cw*03:04 Cw*04:01
15 A*33:03 A*11:01 NP9 41–55 RRPQGLPNNIASWFT CD8 1.54
B*58:01 B*55:02 NP21 101–115 KMKELSPRWYFYYLG CD4 0.58
Cw*03:02 Cw*03:03 3a2 6–20 RFFTLGSITAQPVKI CD8 0.73
16 A*24:20 A*02:06 NP53 261–275 QKRTATKQYNVTQAF CD8 0.53
B*15:02 B*15:25
Cw*08:01 Cw*04:03
a aa, amino acids.
VOL. 85, 2011 T CELLS SPECIFIC FOR A SARS CORONAVIRUS T-CELL EPITOPE 10467
from CD4& T cells. Polyfunctional CD8& T cells producing
IFN-", TNF-$, Mip1$, and Mip1% dominated the memory
SARS-specific CD8& T cell response, although few CD8& T
cells ((20%) produce IL-2 and TNF-$ simultaneously (Fig. 2).
Interestingly, the functional profile of SARS-specific memory
CD8& T cells in SARS-recovered individuals is comparable to
the one exhibited by virus-specific CD8& T cells in HIV non-
progressors and in vaccinia virus-vaccinated individuals (1, 19).
Production of SARS-specific TCR-redirected T cells. The
identification of an HLA-B*40:01-restricted SARS NP-spe-
cific response has practical interest since HLA-B*40:01 is an
HLA-class I allele expressed in 3.0 to 60.0% of the individ-
uals of Asian ethnicities (e.g., Chinese [28.0%], Indians [3.3
to 10.0%], Indonesians [7.2%], Japanese [6.3%], Taiwanese
[6.0 to 60.4%], and Filipinos [30.0%]) (9; see also http:
//allelefrequencies.net/). Importantly, the NP44 (aa 216 to
225) T cell response was not only identified in three of the
six HLA-B*40:01-positive individuals analyzed here but was
also described in other T cell studies with SARS-CoV-in-
fected individuals (11, 18). For example, in a study by Li et
al. (11), 11% of the SARS subjects analyzed gave positive T
cell responses against the peptide region containing NP44
(aa 211 to 225). Even though in that study the HLA restric-
tion and fine specificity of the responses were not deter-
mined, the data confirmed the association of the NP44 (aa
216 to 225) SARS T cell response with recovery from infec-
tion.
Taking into consideration the potential importance of this
SARS-specific CD8& T cells in disease recovery and on the fact
that the SARS-CoV NP protein is highly conserved (99%)
between different SARS-CoV isolates (22), we sought to clone
their $ and % T cell receptor chains of NP44 (aa 216 to 225)
CD8& T cells and use them to redirect the specificity of lym-
phocytes of subjects lacking SARS-specific memory T cells.
Different CD8& T cell clones specific for NP44 (aa 216 to
225) were selected through limiting dilution of NP44-specific
CD8& T cells sorted using FACS and expanded from the
PBMC of one of the HLA-B*40:01-positive individuals (SARS
patient 1) (Fig. 3A). A SARS NP44-specific CD8& T cell clone
(clone 2) was selected based on its high level of responsiveness
to NP44 peptide-pulsed target cells (Fig. 3A). The TCR %
chain of this T cell clone was then determined using a com-
mercial kit, IO Test Beta Mark (Beckman Coulter) and found
to express TCR receptor variable region 4.3 (TRB V%4.3) (Fig.
3B). Subsequently, the T cell receptor $ and % chains were
cloned and further confirmed by sequence analysis of the
cDNA clones. The T cell clone expressed a single TCR $ chain
of V$4.0/J$28.0 and a % chain of V%4.3/J%2.1/D%1.0, as de-
termined using IMGT/V-Quest (2; http://www.imgt.org). A re-
combinant retroviral construct containing the $ and % chains of
the SARS NP44 TCR was then generated as previously de-
scribed (8), and the expression and function of the introduced
TCR into naive lymphocytes were tested.
Peripheral blood lymphocytes of healthy individuals were
transduced and expanded in vitro and stained with anti-V%4.3
and anti-CD3. Mock-transduced T cells represent the fre-
quency of endogenous, naturally occurring V%4.3& T cells.
After transduction with the SARS NP44 TCR, the T cell pop-
ulation showed a frequency of 38.5% V%4.3& T cells (both
CD8& and CD8) populations) (Fig. 3C). Proper pairing of $
and % TCRs was then directly analyzed with functional assays
to test the ability of TCR-transduced T cells in recognizing
NP44 peptide-pulsed HLA-B*40:01-positive target cells. Fig-
ure 3D shows that the introduced TCR endowed SARS spec-
ificity to a large proportion of transduced CD8 T cells (34.1%
IFN-"& and 47.5% CD107a&, respectively).
The functional avidity of SARS-specific TCR-redirected T
cells was compared to the one of NP44-specific CD8& T cell
clones isolated from a SARS-recovered patient. Target cells
were pulsed with decreasing concentrations of the NP44 aa 216
to 225 peptide, and Fig. 3E shows that the TCR-redirected T
cells were activated by HLA-B*40:01 EBV-LCL loaded with
0.1 ng of NP44 peptide/ml, a sensitivity of recognition similar
to that seen with the NP44-specific CD8& T cell clone. These
data showed that TCR gene transfer is able to reconstitute
SARS-specific T cells with a functional avidity similar to the
SARS-memory CD8& T cells present in subjects recovered
from natural infection. Importantly, both TCR-redirected and
“natural” SARS-specific CD8& T cells were able to recognize
target cells infected with recombinant vaccinia virus expressing
the NP protein (Fig. 3F), indicating that both the CD8& T cell
populations can recognize not only peptide-pulsed cells but
also the processed product of endogenously synthesized NP44
SARS antigen.
FIG. 2. Cytokine production profile of representative CD4& and CD8& T cell responses. Target cells were incubated with 3a2 (aa 6 to
20)-specific CD4& T cells or NP44 (aa 216 to 225)-specific CD8& T cells in the presence of brefeldin A and stained with antibodies against
Th1/Th2-associated cytokines (A) and inflammatory cytokines (B). Responses are grouped and color-coded according to the number of cytokines
produced. The data are summarized in pie charts, with every slice representing the fraction of the total response that consists of CD8& T cells
positive for the cytokines indicated on the right.
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Functional profiles of natural and TCR-redirected SARS-
specific T cells. T cells producing multiple cytokines (i.e.,
IFN-", TNF-$, Mip1%, and IL-2) are associated with better
control of HIV infection and with vaccination efficacy (1, 19),
suggesting that T cell polyfunctionality is an important param-
eter that defines protective antiviral immunity. Furthermore,
the CD8& T cell release of chemokines such as Mip1$ and
Mip1% has been associated with the recruitment of effector
cells and could be important at the peripheral sites of viral
infection (20).
We therefore analyzed whether TCR-redirected T cells dis-
play a similar polyfunctional profile compared to SARS-spe-
cific memory CD8 T cells. TCR-redirected T cells specific for
NP44 (aa 216 to 225) were engineered from PBMC of three
FIG. 3. Production of SARS-specific TCR-redirected T cells. (A) Isolation of NP44-specific T cell clone. NP44-specific CD8& T cells were
purified by FACS and cloned by limiting dilution assay. Clonal populations were expanded and subjected to two rounds of screening for CD107a&
and/or IFN-"& CD8& T cells. (B) Determination of the TCR % chain of the NP44-specific T cell clone by staining for the various TCR % variable
regions (TRBV). The percentages of the CD8& T cells positive for the various TRBV are indicated. Further cloning of the TCR $ and % chains
of the T cell clone was carried out, and peripheral blood lymphocytes from a healthy donor were transduced with the SARS NP44 TCR retroviral
vector. (C) Dot plot of V%4.3 expression in mock- or NP44-TCR transduced T cells from a representative healthy donor. The percentages of
V%4.3& T cells (CD8& and CD8)) after gating on the CD3& fraction of the PBMC are indicated in the upper and lower right quadrants. (D) Dot
plot from representative SARS NP44-transduced T cells incubated with target cells loaded with NP44 peptide. The percentages of IFN-"& or
CD107a& T cells (CD8& and CD8)) after gating on the CD3& fraction of the PBMC are indicated in the upper and lower right quadrants. (E) For
functional avidity, NP44-specific T cell clone or SARS NP44 TCR-transduced T cells were incubated with target cells pulsed with the indicated
concentrations of NP44 peptide. The percent maximum IFN-"& response was plotted against the concentrations of NP44 peptide, whereby the
maximum IFN-"& response at 1 !g/ml was set as 100%. The data shown are the mean values of three experiments with standard error bars as
indicated. (F) For recognition of the endogenous SARS antigen, the SARS NP44-specific T cell clone and NP44 TCR-transduced T cells were
incubated with target cells infected with a vaccinia virus construct expressing the SARS spike (S) (negative control) or nucleocapsid (NP) protein
at an MOI of 5 and stained for CD107a. The percentages of CD107a& cells in the total CD8& population are shown.
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different SARS-negative healthy individuals. Polychromatic
flow cytometry with the same antibody panels and gating strat-
egy that were used for the analysis of SARS-specific natural
CD8& and CD4& T cells was utilized. Figure 4 shows (in the
lower portion of each panel) that TCR-redirected T cells have
a cytokine production profile similar to that of SARS-specific
memory CD8& T cells analyzed in three different patients
(upper portion of each panel). IFN-", TNF-$, MiP1$, and
Mip1% were preferentially produced by TCR redirected T
cells, while only very few TCR-redirected T cells produced
IL-2, GM-CSF, and IL-8. The polyfunctionality pattern of
TCR-redirected T cells showed a decreased frequency of
CD8& T cells able to produce four cytokines in comparison to
the natural SARS memory CD8& T cells, whereas a compara-
ble frequency of CD8& T cells producing three cytokines
(IFN-", MiP-1$, and Mip-1%) or two cytokines (IFN-" and
TNF-$) was observed (Fig. 4). Taken together, these data
indicate that the NP44 TCR-transduced T cells can achieve
functions similar to those obtained directly from a SARS-
recovered individual.
In conclusion, we have identified in subjects that recovered
from SARS-CoV infection a new immunodominant HLA-
FIG. 4. Cytokine production profile of NP44-specific CD8& T cells. HLA-B*40:01-positive target cells were pulsed with 1 !g of NP44
peptide/ml or left unpulsed. These cells were then incubated with NP44-specific T cells from a SARS-recovered individual (upper panels) or the
SARS NP44 TCR-transduced T cells (lower panels) in the presence of brefeldin A and stained with antibodies against Th1/Th2-associated
cytokines (A) or inflammatory cytokines (B). Each graph shows the data for NP44-specific CD8& T cells from three SARS-recovered individuals
or the SARS NP44 TCR-transduced T cells from three healthy donors. The data are expressed as the percentage of the total number of CD8&
T cells expressing the different possible combinations of cytokines. Responses are grouped and color-coded according to the number of cytokines
produced. The data are summarized in pie charts, with every slice representing the fraction of the total response that consists of CD8& T cells
positive for the given number of cytokines produced.
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B*40:01-restricted SARS-specific CD8& T cell response. We
also demonstrated the feasibility of producing in vitro, from the
lymphocytes of healthy subjects, SARS-specific CD8& T cells
that have an avidity and cytokine production profile similar to
that of the SARS-specific memory CD8& T cells present in
SARS-recovered individuals. One recent study showed that
adoptive transfer of in vitro-cultured SARS-specific CD8& T
cells can significantly enhance survival and virus clearance in
SCID mice that were infected with mouse-adapted SARS-CoV
(MA15) (32). Moreover, adoptive transfer of virus-specific T
cells is becoming an accepted treatment to prevent EBV and
HCMV reactivation (4, 7). SARS-specific TCR-redirected T
cells thus represent an additional potential prophylactic or
therapeutic treatment for this life-threatening infection.
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